Applicant: Polyak et al.

Serial No.:

Filed

riiea

Page

: 2 of 14

Attorney's Docket No.: 00530-116US1 / DFCI 853.02

10/550162

JC17 Rec'd PCT/PTO 20 SEP 2005

## Amendments to the Specification:

Please replace the paragraph beginning at page 2, line 14, with the following amended paragraph:

--Another aspect of the invention is a method of determining the likelihood of a breast cancer being DCIS or invasive breast cancer. The method includes the steps of: (a) providing a test sample of breast tissue; (b) determining the level of expression in the test sample of a gene selected from the group consisting of a gene encoding CD74, a gene encoding MGC2328, a gene encoding S100A7, a gene encoding KRT19, a gene encoding trefoil factor 3 (TFF3), a gene encoding osteonectin, and a gene identified by a SAGE tag consisting of the nucleotide sequence CTGGGCGCCC (SEQ ID NO:1109); and (c) determining whether the level of expression of the selected gene in the test sample more closely resembles the level of expression of the selected gene in control cells of (i) DCIS or (ii) invasive breast cancer; and (d) classifying the test sample as: (i) likely to be DCIS if the level of expression of the gene in the test sample more closely resembles the level of expression of the gene in DCIS cells; or (ii) likely to be invasive breast cancer if the level of expression of the gene in the test sample more closely resembles the level of expression of the gene in the test sample more closely resembles the level of expression of the gene in the test sample more closely resembles the level of expression of the gene in the test sample more closely resembles the level of expression of the gene in the test sample more closely resembles the level of expression of the gene in the test sample more closely resembles the level of expression of the gene in invasive breast cancer cells.--

Please replace the paragraph beginning at page 6, line 19, with the following amended paragraph:

--Also embodied by the invention is an array that includes a substrate having at least 10 addresses, each address having disposed on it a capture probe that includes a nucleic acid sequence consisting of a tag nucleotide sequence selected from those listed in Tables 1-5, 7-10, 15, and 16. The tag nucleotide sequence can be one that corresponds to a gene encoding a protein selected from the group consisting of fatty acid synthase (FASN), trefoil factor 3 (TFF3), X-box binding protein 1 (XBP1), interferon alpha inducible protein 6-16 (IFI-6-16), cysteinerich protein 1 (CRIP1), interferon-stimulated protein 15 kDa (ISG15), interferon alpha inducible protein 27 (IFI27), brain expressed X linked 1 (BEX1), helicase/primase protein (LOC150678),

Applicant: Polyak et al. Attorney's Docket No.: 00530-116US1 / DFCI 853.02

Serial No. : Filed :

Page : 3 of 14

anaphase promoting complex subunit 11 (ANAPC11), Fer-1-like 4 (FER1L4), psoriasin, connective tissue growth factor (CTGF), regulator of G-protein signaling 5 (RGS5), paternally expressed 10 (PEG10), osteonectin (SPARC), LOC51235, CD74, MGC23280, Invasive Breast Cancer 1 (IBC-1), Apolipoprotein D (APOD), carboxypeptidase B1 (CPB1), retinal binding protein 1 (RBP1), FLJ30428, calmodulin-like skin protein (CLSP), nudix (NUDT8), MGC14480, interleukin-1β (ILβ), macrophage inhibitory protein 1α (MIP1α), cathepsins F, K, and L, MMP2, PRSS11, thrombospondin 2, SERPING1, cytostatin C, TIMP3, platelet-derived growth factor receptor β-like (PDGFRBL), a collagen, collagen triple helix repeat containing 1 (CTHRC1), CXCL12, CXCL14, and a protein encoded by a gene identified by a SAGE tag consisting of the nucleotide sequence CTGGGCGCCC (SEQ ID NO:1109). The array can contain at least 25 addresses; at least 50 addresses; at least 100 addresses; at least 200 addresses; or at least 500 addresses.--

Please replace the paragraph beginning at page 7, line 12, with the following amended paragraph:

--Another kit provided by the invention is one that contains at least 10 antibodies each of which is specific for a different protein encoded by a gene identified by a tag selected from the group consisting of the tags listed in Tables 1-5, 7-10, 15, and 16. The antibodies can, for example, be specific for a protein selected from the group consisting of fatty acid synthase (FASN), trefoil factor 3 (TFF3), X-box binding protein 1 (XBP1), interferon alpha inducible protein 6-16 (IF1-6-16), cysteine-rich protein 1 (CRIP1), interferon-stimulated protein15 kDa (ISG15), interferon alpha inducible protein 27 (IFI27), brain expressed X linked 1 (BEX1), helicase/primase protein (LOC150678), anaphase promoting complex subunit 11 (ANAPC11), Fer-1-like 4 (FER1L4), psoriasin, connective tissue growth factor (CTGF), regulator of G-protein signaling 5 (RGS5), paternally expressed 10 (PEG10), osteonectin (SPARC), LOC51235, CD74, MGC23280, Invasive Breast Cancer 1 (IBC-1), Apolipoprotein D (APOD), carboxypeptidase B1 (CPB1), retinal binding protein 1 (RBP1), FLJ30428, calmodulin-like skin protein (CLSP), nudix (NUDT8), MGC14480, interleukin-1β (ILβ), macrophage inhibitory

Applicant: Polyak et al. Attorney's Docket No.: 00530-116US1 / DFCI 853.02

Serial No. : Filed :

Page : 4 of 14

protein 1α (MIP1α), cathepsins F, K, and L, MMP2, PRSS11, thrombospondin 2, SERPING1, cytostatin C, TIMP3, platelet-derived growth factor receptor β-like (PDGFRBL), a collagen, collagen triple helix repeat containing 1 (CTHRC1), CXCL12, CXCL14, and a protein encoded by a gene identified by a SAGE tag consisting of the nucleotide sequence CTGGGCGCCC (SEQ ID NO:1109). The kit can contain at least 25 antibodies; at least 50 antibodies; at least 100 antibodies; at least 200 antibodies; or at least 500 antibodies.--

Please replace the paragraph beginning at page 29, line 24, with the following amended paragraph:

--Intrakine methodologies are conceptually similar to the degrakine methodology. Instead of the Vpu protein, a signal sequence that serves to direct proteins containing it to the ER (e.g., the four amino acid KDEL (SEQ ID NO:19[[56]]55) sequence) is fused to the ligand protein X (or a fragment of the protein X ligand that retains the ability to bind to the receptor for the ligand protein X) [Coffield et al. (2003); Chen et al. (1997)].--